Editor's note: Recently, Shenzhen Huanuo Biological Technology Co., Ltd. (referred to as "Huano Bio") has announced that it has obtained Guoqian Venture Capital Management (Suzhou) Co., Ltd. (referred to as "Guoqian Venture Capital"), Shenzhen Chuangsai Fund The Investment Management Co., Ltd. has a total of 6 million yuan in Pre-A round financing, and its China Venture Capital has invested 3 million yuan.
Shenzhen Huanuo Biological Technology Co., Ltd. (formerly known as Rebecca) was established in 2017. In fact, the research and development of Huanuo Biological began in 2015. After more than three years of development, Huanuo Biological has established a team of overseas returnees, professors and More than 10 teams of R & D, production and management led by experts from the National "Thousand Talents Program" of the Central Organization Department have developed two types of products for the body surface and body hemostatic field.
Company founder: Dr. Wang Huanan
The founder and chairman of the company, Dr. Wang Huanan, is a recipient of the National "Young Thousand Talents Program" and a young scholar of Rubicon in the Netherlands. He has engaged in years of research in the field of biomaterials at the University of Niegen in the Netherlands and Harvard University in the United States. Has a solid theoretical foundation and rich practical experience in the field of biomaterial design and development. He has obtained a Ph.D. in Biomedical Engineering from Sichuan University and a double Ph.D. in Medical Science from Nijmegen University, the Netherlands.
Dr. Wang Huanan said: The medical device industry in China is a rising industry with huge room for growth, but at the same time, China's own industry and technology are seriously lagging behind, and high-value device products are generally monopolized by developed countries in Europe and America, and the products are expensive. It is the original intention of Huanuo Biology to break the monopoly position of European and American high-value medical equipment products, develop new products and technologies with higher cost performance, better performance than European and American medical equipment products, and have independent intellectual property rights. At present, the company has successfully developed self-healing gel metamaterial platform technology with independent intellectual property rights, and continues to expand the development of high-value medical equipment products based on this platform technology, product design bone wound repair, medical and aesthetic tissue filling, oral repair filling, In the five major areas of skin wound repair and 3D bioprinting, the core products have the characteristics of minimally invasive and intelligent, and the related technologies are at the international frontier. Huanuo Biotech will pursue the concept of technology supremacy, continuous innovation and quality core, and be a national brand in the field of high-end medical equipment.
Company founder: Gong Chuanbo
Gong Chuanbo, deputy general manager of the company, said: Huanuo Bio is currently building a 1,000 square meter GMP standard ultra-clean production line. This will be the first large-scale medical-grade self-repairing metamaterial production line in China. It is expected that the annual output value will be achieved when it is operating at full capacity. Production of 300 million yuan of hemostatic gel (powder) and periodontal anti-inflammatory gel products. The company expects to complete the approval of sales of three types of medical devices for hemostatic preparations and oral products in the next three years. It conservatively estimates that the products will be marketed in 2021 and will achieve annual sales of 100 million yuan three years later. The team is honored to be able to cooperate with Guoqian Venture Capital, a professional investment institution in the medical device field, to enable rapid development of R & D; at the same time, the resource integration capabilities of Guoqian Venture Capital also provide help for the company's future development.
Chairman of Guoqian Venture Capital: Dr. Zhang Xu
Dr. Zhang Xu, Chairman of Guoqian Venture Capital, said: The team of Huanuo Biology and Dr. Wang Huanan have in-depth research in the field of self-healing metamaterials and regenerative medicine, with good prospects, and their R & D layout is highly competitive in the world. Support its development.
Guoqian Venture Capital Management (Suzhou) Co., Ltd.
Guoqian Venture Capital was jointly established by Dr. Zhang Xu and other six national "Thousand Talents Plan" experts in the medical device related field, and the Suzhou Medical Institute of the Chinese Academy of Sciences and other shareholders.
Based on the business philosophy of "achieving the dreams of others", Guoqian Medical takes the national "Thousand Talents Plan" experts and its radiating high-end scientific and technological talents as the core, and takes medical devices, in vitro diagnostic reagents, medical services and other main fields as its talent projects In the process of introduction, innovation and entrepreneurship project evaluation, and the transformation of scientific and technological achievements, high-quality entrepreneurial projects are sought. The value of the project is discovered and the project is discovered through private equity investment, talent project introduction and service, entrepreneurial project acceleration and empowerment, industrial investment and integration. Value, build a cluster and ecosystem of medical and health industries.